APOA1 and type 2 diabetes mellitus: Interestingly, the ex vivo treatment of HDLs from patients with T2D using an apoA-I mimetic peptide with the capability to bind oxidized fatty acids (D-4F) restored the antioxidant capacity of HDLs in individuals with T2D [58].